Skip to main content
SpringerLink
Log in

Vulvakarzinom – bei weitem kein ungefährliches Alterskarzinom

Moderne Therapieoptionen

Vulvar cancer – far from a harmless carcinoma of the elderly

Modern therapy options

  • Leitthema
  • Published:
Der Gynäkologe Aims and scope

Zusammenfassung

Das Vulvakarzinom ist nicht mehr ein Alterskarzinom: Die Zunahme dieser Tumorentität um 300–400% in der letzten Dekade ist vor allem durch das gehäufte Auftreten dieser Tumoren bei jungen Frauen bedingt. Abhängig vom Alter der Patientin ist an diesen Tumoren in 30–60% eine Infektion mit humanen Papillomviren (HPV) ursächlich beteiligt. Die Prädilektionsstelle ist die Region zwischen Klitoris und Urethra (etwa 40%). Die Behandlung ist die Resektion in sano oder (partielle) Vulvektomie und eine inguinofemorale Lymphknotenentfernung. Als neue Therapieoptionen ist die Sentinel-Lymphonodektomie und die Deckung des Defektes mit lokoregionären Lappen zur Verbesserung des ästhetischen wie des funktionellen Ergebnisses zu sehen.

Abstract

Nowadays, vulvar cancer is not merely a carcinoma of elderly women. The incidence of this tumor entity has increased 3–4 fold in the last few decades mainly due to the increasing number of young women presenting with these tumors. Persistent infection with high risk human papillomavirus is responsible for development of these lesions in 30–60% of the cases, depending on the age of the women. About 40% of the tumors are located between the clitoris and the urethra. Standard treatment is tumor resection with sufficient margins or (partial) vulvectomy and complete inguinofemoral lymphadenectomy. New therapy options are resection of the sentinel nodes only and reconstruction of the vulva with local flaps to improve aesthetic and functional outcome.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1
Abb. 2
Abb. 3
Abb. 4
Abb. 5
Abb. 6
Abb. 7

Literatur

  1. http://www.krebsinfo.de/ki/epi-daten/pdf/inz2001.pdf

  2. Engel JS-FG, Hölzel D (2001) Epidemiologie. In: Kimmig: Tumormanual Vulvakarzinom, Zuckschwerdt, München, S 1–4

  3. Al-Ghamdi A, Freedman D, Miller D et al (2002) Vulvar squamous cell carcinoma in young women: a clinicopathologic study of 21 cases. Gynecol Oncol 84:94–101

    Article  PubMed  CAS  Google Scholar 

  4. Carter J, Carlson J, Fowler J et al (1993) Invasive vulvar tumors in young women–a disease of the immunosuppressed? Gynecol Oncol 51:307–310

    Article  PubMed  CAS  Google Scholar 

  5. Hampl M, Deckers-Figiel S, Hampl JA et al (2008) New aspects of vulvar cancer: changes in localization and age of onset. Gynecol Oncol 109:340–345

    Article  PubMed  Google Scholar 

  6. Hampl M, Ramp U, Bender HG, Kueppers V (2006) A case of a pT3, HPV 52-positive vulvar carcinoma in an 18-year-old woman. Gynecol Oncol 101:530–533

    Article  PubMed  Google Scholar 

  7. Jones RW, Baranyai J, Stables S (1997) Trends in squamous cell carcinoma of the vulva: the influence of vulvar intraepithelial neoplasia. Obstet Gynecol 90:448–452

    Article  PubMed  CAS  Google Scholar 

  8. Joura EA, Losch A, Haider-Angeler MG et al (200) Trends in vulvar neoplasia. Increasing incidence of vulvar intraepithelial neoplasia and squamous cell carcinoma of the vulva in young women. J Reprod Med 45:613–615

    Google Scholar 

  9. Judson PL, Habermann EB, Baxter NN et al 82006) Trends in the incidence of invasive and in situ vulvar carcinoma. Obstet Gynecol 107:1018–1022

  10. Messing MJ, Gallup DG (1995) Carcinoma of the vulva in young women. Obstet Gynecol 86:51–54

    Article  PubMed  CAS  Google Scholar 

  11. Hampl M, Wentzensen N, Vinokurova S et al (2007) Comprehensive analysis of 130 multicentric intraepithelial female lower genital tract lesions by HPV typing and p16 expression profile. J Cancer Res Clin Oncol 133:235–245

    Article  PubMed  CAS  Google Scholar 

  12. Hampl M, Sarajuuri H, Wentzensen N et al (2006) Effect of human papillomavirus vaccines on vulvar, vaginal, and anal intraepithelial lesions and vulvar cancer. Obstet Gynecol 108:1361–1368

    Article  PubMed  CAS  Google Scholar 

  13. Jones RW, Rowan DM, Stewart AW (2005) Vulvar intraepithelial neoplasia: aspects of the natural history and outcome in 405 women. Obstet Gynecol 106:1319–1326

    Article  PubMed  Google Scholar 

  14. Seters M van, Beurden M van, Craen AJ de (2005) Is the assumed natural history of vulvar intraepithelial neoplasia III based on enough evidence? A systematic review of 3322 published patients. Gynecol Oncol 97:645–651

    Article  PubMed  Google Scholar 

  15. Zaloudek CRJ Differentiated vulva intraepithelial neoplasia (VIN) (2005) An unrecognised form of high grade VIN associated with keratinising squamous cell carcinoma of the vulva. Pathol Case Rev 10:35–40

    Article  Google Scholar 

  16. zur Hausen H (2002) Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer 2:342–350

    Article  Google Scholar 

  17. Baumann KH, Muller O, Naujok HB et al (2010) Small-area analysis of incidence and localisation of vulvar cancer. J Oncol 512032

  18. Hampl M (2011) Vulvakarzinome der vorderen Kommissur-eine zunehmende Tumorentität. gyn 16

  19. Schomann P (2007) Schnellwachsende, altersunabhängige, vulväre, erosive, subklitorale Neoplasien. gyn 12:69–76

    Google Scholar 

  20. Stehman FB, Bundy BN, Dvoretsky PM, Creasman WT (1992) Early stage I carcinoma of the vulva treated with ipsilateral superficial inguinal lymphadenectomy and modified radical hemivulvectomy: a prospective study of the Gynecologic Oncology Group. Obstet Gynecol 79:490–497

    PubMed  CAS  Google Scholar 

  21. Hampl M, Hantschmann P, Michels W, Hillemanns P (2008) Validation of the accuracy of the sentinel lymph node procedure in patients with vulvar cancer: results of a multicenter study in Germany. Gynecol Oncol 111:282–288

    Article  PubMed  Google Scholar 

  22. Van der Zee AG, Oonk MH, De Hullu JA et al (2008) Sentinel node dissection is safe in the treatment of early-stage vulvar cancer. J Clin Oncol 26:884–889

    Article  Google Scholar 

  23. Puig-Tintore LM, Ordi J, Vidal-Sicart S et al (2003) Further data on the usefulness of sentinel lymph node identification and ultrastaging in vulvar squamous cell carcinoma. Gynecol Oncol 88:29–34

    Article  PubMed  Google Scholar 

  24. Moore RG, Granai CO, Gajewski W et al (2003) Pathologic evaluation of inguinal sentinel lymph nodes in vulvar cancer patients: a comparison of immunohistochemical staining versus ultrastaging with hematoxylin and eosin staining. Gynecol Oncol 91:378–382

    Article  PubMed  Google Scholar 

  25. Gaarenstroom KN, Kenter GG, Trimbos JB et al (2003) Postoperative complications after vulvectomy and inguinofemoral lymphadenectomy using separate groin incisions. Int J Gynecol Cancer 13:522–527

    Article  PubMed  CAS  Google Scholar 

  26. Nestle-Krämling C, Janni W, Hampl M (2009) Defektdeckung an der Vulva mit plastisch-rekonstruktiven Verfahren – Indikationen, Techniken, Ergebnisse. Geburtsh Frauenheilk 69:1082–1090

    Article  Google Scholar 

  27. Hockel M, Dornhofer N (2008) Vulvovaginal reconstruction for neoplastic disease. Lancet Oncol 9:559–568

    Article  PubMed  Google Scholar 

  28. Lister GD, Gibson T (1972) Closure of rhomboid skin defects: the flaps of Limberg and Dufourmentel. Br J Plast Surg 25:300–314

    Article  PubMed  CAS  Google Scholar 

  29. Moschella F, Cordova A (2000) Innervated island flaps in morphofunctional vulvar reconstruction. Plast Reconstr Surg 105:1649–1657

    Article  PubMed  CAS  Google Scholar 

  30. Yii NW, Niranjan NS (1996) Lotus petal flaps in vulvo-vaginal reconstruction. Br J Plast Surg 49:547–554

    Article  PubMed  CAS  Google Scholar 

  31. Lindell G, Nasman A, Jonsson C et al (2010) Presence of human papillomavirus (HPV) in vulvar squamous cell carcinoma (VSCC) and sentinel node. Gynecol Oncol 117:312–316

    Article  PubMed  Google Scholar 

  32. Parkin DM (2006) The global health burden of infection-associated cancers in the year 2002. Int J Cancer 118:3030–3044

    Article  PubMed  CAS  Google Scholar 

  33. Joura EA, Kjaer SK, Wheeler CM et al (2008) HPV antibody levels and clinical efficacy following administration of a prophylactic quadrivalent HPV vaccine. Vaccine 26:6844–6851

    Article  PubMed  CAS  Google Scholar 

  34. Paavonen J, Jenkins D, Bosch FX et al (2007) Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet 369:2161–2170

    Article  PubMed  CAS  Google Scholar 

  35. Villa LL, Costa RL, Petta CA et al (2006) High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 yrs of follow-up. Br J Cancer 95:1459–1466

    Article  PubMed  CAS  Google Scholar 

  36. Descamps D, Hardt K, Spiessens B et al (2009) Safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine for cervical cancer prevention: A pooled analysis of 11 clinical trials. Hum Vaccin 5

  37. Garland SM, Hernandez-Avila M, Wheeler CM et al (2007) Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 356:1928–1943

    Article  PubMed  CAS  Google Scholar 

  38. Joura EA, Leodolter S, Hernandez-Avila M et al (2007) Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials. Lancet 369:1693–1702

    Article  PubMed  CAS  Google Scholar 

  39. Paavonen J, Naud P, Salmeron J et al (2009) Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 374:301–314

    Article  PubMed  CAS  Google Scholar 

  40. Monsonego J, Cortes J, Greppe C et al (2010) Benefits of vaccinating young adult women with a prophylactic quadrivalent human papillomavirus (types 6, 11, 16 and 18) vaccine. Vaccine 28:8065–8072

    Article  PubMed  CAS  Google Scholar 

  41. DGGG (2009) S2k-Leitlinie Diagnostik und Therapie des Vulvakarzinoms und seiner Vorstufen, S 28–29

  42. Robert-Koch-Institut (2007) Epidemiologisches Bulletin vom 23.03.2007; 12, 97–103

  43. Ansitz A, van der Velden J (2000) Surgical intervention for early sqamous cell carcinoma of the vulva. Cochrane Database Syst Rev 2000 (2)

  44. Joura (2010) Abstract IPC Montreal

Download references

Interessenkonflikt

Keine Angaben

Author information

Authors and Affiliations

  1. Universitätsfrauenklinik, Heinrich Heine Universität, Moorenstr. 5, 40225, Düsseldorf, Deutschland

    M. Hampl, G. Bauerschmitz & W. Janni

Authors
  1. M. Hampl
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. G. Bauerschmitz
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. W. Janni
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M. Hampl.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hampl, M., Bauerschmitz, G. & Janni, W. Vulvakarzinom – bei weitem kein ungefährliches Alterskarzinom. Gynäkologe 44, 684–693 (2011). https://doi.org/10.1007/s00129-011-2767-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00129-011-2767-x

Schlüsselwörter

Keywords

Search

Navigation